Thiazolidinediones News and Research

RSS

Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026

Repurposed diabetes drugs boost CAR T therapy effectiveness in bladder cancer

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC remains around five to ten percent.

12 Sep 2025

Could chlorophyll become the next antidiabetic therapy?

Research highlights chlorophyll's role in blood sugar regulation and insulin mimicry, though safety risks and lack of human trials warrant caution.

20 Aug 2025

Diabetes drug shows promise for treating prostate cancer

An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is central to the regulation of metabolic processes, can also influence the growth of prostate cancer cells.

6 May 2025

Keto controversy? Experts say it’s here to stay

Low-carb and ketogenic diets offer sustainable solutions for chronic disease, enhancing metabolic health and supporting weight loss through dietary changes.

18 Mar 2025

How genetic traits contribute to earlier diabetes onset and metabolic challenges in South Asians

The study uncovers genetic factors driving early type 2 diabetes in South Asians, highlighting risks of insulin dependence and medication response challenges.

28 Nov 2024

Semaglutide may reduce Alzheimer's risk in diabetics

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease.

25 Oct 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

Semaglutide reduces heart risks in overweight and obese individuals without diabetes

The SELECT trial found that semaglutide significantly reduces cardiovascular events in individuals with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or changes in HbA1c levels.

26 Jun 2024

Restoring insulin sensitivity without TZD side effects

Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease.

13 Apr 2024

Embracing nature's medicine: exploring medicinal plants for diabetes treatment

Researchers described 20 medicinal plants, their bioactive phytochemical components, therapeutic potential, modes of action, and prospects and ability to combat diabetes mellitus.

27 Jul 2023

The effect of diabetes medications on the risk of developing cancer

In an attempt to discern the risk of cancer posed by certain diabetic drugs as well, the authors of a recent paper performed a systematic review and meta-analysis of all studies over the past ten years dealing with this topic.

25 Jul 2023

Study reveals novel role of PPARγ acetylation in macrophages in impairing adipose tissue function

As a chronic pro-inflammatory disease, obesity is closely associated with the development of various diseases such as type 2 diabetes, cardiovascular disease and cancers. Obesity is now a major concern for public health.

30 Dec 2022

Using cationic nanonmaterials to target visceral adiposity

Researchers have long been working on how to treat obesity, a serious condition that can lead to hypertension, diabetes, chronic inflammation, and cardiovascular diseases.

1 Dec 2022

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

In a new study, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs.

3 Aug 2022

Drug combinations may help to slow the progression of diabetic kidney disease

A mouse study led by Washington University School of Medicine in St. Louis suggests that combining SGLT2 inhibitors — a newer class of diabetes medications that lowers blood sugar — with older diabetes drugs may help to slow the progression of diabetic kidney disease.

15 Jun 2022